Literature DB >> 10971514

TNFA promoter polymorphism and susceptibility to brucellosis.

A Caballero1, M J Bravo, A Nieto, J D Colmenero, A Alonso, J Martín.   

Abstract

The aim of this study was to investigate the possible influence of the tumor necrosis factor alpha (TNFA) gene promoter polymorphisms and HLA class II genes on the susceptibility to or development of human brucellosis. TNFA genotypes (at positions -308 and -238) were determined in 59 patients with brucellosis and 160 healthy controls by polymerase chain reaction-restriction fragment length polymorphism. There were no significant differences between the patients and the controls for the TNFA-238 genotypes. However, when the overall TNFA-308 genotype distribution of the brucella patients was compared with that of the control subjects, a significant skewing was observed (P = 0.02). The TNFA-308.1/2 genotype was present at significantly higher frequency in the total patient as a whole compared with control subjects (30% versus 15%; P = 0.01, odds ratio (OR) 2.49, 95% confidence interval (CI) 1.16-5.33). No statistically significant differences in the distribution of HLA-DRB1 or DQB1 alleles were observed between brucella patients and control subjects. Stratification to correct for interdependence of TNFA-308.2 and HLA-DR3 alleles confirmed that, in spite of their strong linkage disequilibrium, the association of TNFA-308.2 with brucellosis was independent of HLA-DR3.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971514      PMCID: PMC1905734          DOI: 10.1046/j.1365-2249.2000.01331.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus.

Authors:  M J Rood; M V van Krugten; E Zanelli; M W van der Linden; V Keijsers; G M Schreuder; W Verduyn; R G Westendorp; R R de Vries; F C Breedveld; C L Verweij; T W Huizinga
Journal:  Arthritis Rheum       Date:  2000-01

2.  HLA studies in brucellar spondylitis.

Authors:  G S Alarcón; E Gotuzzo; S A Hinostroza; C Carrillo; T S Bocanegra; L R Espinoza
Journal:  Clin Rheumatol       Date:  1985-09       Impact factor: 2.980

3.  Changing trends in the epidemiology of human brucellosis in California from 1973 to 1992: a shift toward foodborne transmission.

Authors:  B B Chomel; E E DeBess; D M Mangiamele; K F Reilly; T B Farver; R K Sun; L R Barrett
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

4.  Tumor necrosis factor production in patients with leprosy.

Authors:  P F Barnes; D Chatterjee; P J Brennan; T H Rea; R L Modlin
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

5.  Macrophage control of Brucella abortus: role of reactive oxygen intermediates and nitric oxide.

Authors:  X Jiang; B Leonard; R Benson; C L Baldwin
Journal:  Cell Immunol       Date:  1993-10-15       Impact factor: 4.868

6.  Control of IL-12 and IFN-gamma production in response to live or dead bacteria by TNF and other factors.

Authors:  Y Zhan; C Cheers
Journal:  J Immunol       Date:  1998-08-01       Impact factor: 5.422

7.  Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria.

Authors:  W McGuire; A V Hill; C E Allsopp; B M Greenwood; D Kwiatkowski
Journal:  Nature       Date:  1994-10-06       Impact factor: 49.962

8.  Common west African HLA antigens are associated with protection from severe malaria.

Authors:  A V Hill; C E Allsopp; D Kwiatkowski; N M Anstey; P Twumasi; P A Rowe; S Bennett; D Brewster; A J McMichael; B M Greenwood
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

9.  HLA antigens in brucellosis.

Authors:  E Pareja; F J Bonal; P Paule; D Salvatierra; F Garrido
Journal:  Exp Clin Immunogenet       Date:  1985

10.  An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles.

Authors:  A G Wilson; N de Vries; F Pociot; F S di Giovine; L B van der Putte; G W Duff
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  7 in total

1.  Polymorphisms in tumor necrosis factor and other cytokines as risks for infectious diseases and the septic syndrome.

Authors:  Julian Knight
Journal:  Curr Infect Dis Rep       Date:  2007-10       Impact factor: 3.725

Review 2.  Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity.

Authors:  L M Pachman; T O Fedczyna; T S Lechman; J Lutz
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

3.  Brucella suis prevents human dendritic cell maturation and antigen presentation through regulation of tumor necrosis factor alpha secretion.

Authors:  Elisabeth Billard; Jacques Dornand; Antoine Gross
Journal:  Infect Immun       Date:  2007-07-16       Impact factor: 3.441

4.  Association between the IL-10 and IL-6 polymorphisms and brucellosis susceptibility: a meta-analysis.

Authors:  Xiaochun Jin; Yueyuan Wu; Shuzhou Yin; Xu Chen; Youtao Zhang
Journal:  BMC Med Genet       Date:  2020-03-30       Impact factor: 2.103

5.  Evaluation of the relationship between IL-12, IL-13 and TNF-α gene polymorphisms with the susceptibility to brucellosis: a case control study.

Authors:  Sima Kazemi; Asad Vaisi-Raygani; Fariba Keramat; Massoud Saidijam; Ali Reza Soltanian; Mahdi Alahgholi-Hajibehzad; Seyed Hamid Hashemi; Mohammad Yousef Alikhani
Journal:  BMC Infect Dis       Date:  2019-12-09       Impact factor: 3.090

6.  Ex vivo innate immune cytokine signature of enhanced risk of relapsing brucellosis.

Authors:  Kristyn E Feldman; Paul M Loriaux; Mayuko Saito; Iskra Tuero; Homarh Villaverde; Tenaya Siva; Eduardo Gotuzzo; Robert H Gilman; Alexander Hoffmann; Joseph M Vinetz
Journal:  PLoS Negl Trop Dis       Date:  2013-09-05

7.  Whole-Genome Resequencing to Study Brucellosis Susceptibility in Sheep.

Authors:  Xiaolong Li; Qingmin Wu; Xiaoxue Zhang; Chong Li; Deyin Zhang; Guoze Li; Yukun Zhang; Yuan Zhao; Zhaoguo Shi; Weimin Wang; Fadi Li
Journal:  Front Genet       Date:  2021-07-08       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.